Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cellavita HD lower dose
BIOLOGICAL
2 trials
Sponsors
Azidus Brasil
Conditions
Huntington Disease
Phase 1
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
NCT02728115
Azidus Brasil
Huntington Disease
Start: 2017-10-16
End: 2023-12-31
Updated: 2022-11-02
Phase 2
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Completed
NCT03252535
Azidus Brasil
Huntington Disease
Start: 2018-01-15
End: 2021-04-30
Updated: 2025-09-19
Related Papers
A phase I, open-label study of intravenous human dental pulp stem cells (NestaCell®) at two dose levels in patients with Huntington's disease.
2025-11-04
Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study.
2025-08-06
2 citations
Huntington’s Disease Clinical Trials Corner: August 2018
Journal of Huntington s Disease
2018-06-01
31 citations
Huntington’s Disease Clinical Trials Corner: February 2018
2018-01-01
44 citations